Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus’ proprietary oncology diagnostic platform with Bayer’s broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products…

Excerpt from:
Prometheus And Bayer Schering Pharma To Apply Novel Diagnostic Platform To Oncology Therapeutic Candidates

You may also like:

• Slo-Niacin(R), A Non-Prescription Dietary Supplement, Features Nicotinic Acid - The Most Effective Agent For Increasing HDL, ‘Good Cholesterol’
• Better Understanding Of Body’s Response To Fasting May Lead To Therapies For Metabolic Disorders
• UnitedHealth Group Supports Tornado Victims In Minnesota
• Gene Variant Linked to Lower Dementia Risk (CME/CE, with audio)
• Cellceutix Corporation Selects Destum Partners To Partner Psoriasis Compound
• European Medicines Agency Concludes Review Of Modified-Release Oral Opioids Of The WHO Level III Scale For The Management Of Pain
• Decreasing Atherosclerosis Risk By Inhibiting Fatty Acids In Immune Cells
• Identification Of Key Stem Cells For Eating And Sex
• First Study To Document Education Effectiveness In Preventing Human-Cause Fires
• AMRI Announces Phase I Study Of Novel Drug For Obesity Treatment